Predictive Value of Preoperative Volume-Based 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Resectable Lung Adenocarcinoma

Sunju Choi, Hye Ryeong Kwon, Hee Young Cho, Kisoo Pahk, Sung Ho Lee, Jae Ho Chung, Hyun Woo Kwon, Sungeun Kim

Research output: Contribution to journalArticle

Abstract

Purpose: This study aimed to investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which are volume-based PET parameters, using 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with surgically resectable lung adenocarcinoma. Methods: We retrospectively evaluated 149 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT before surgical resection. Maximum standardized uptake value (SUVmax), MTV, and TLG of the primary tumor with threshold value of SUVmax 30, 40, and 50% were calculated, respectively. To compare the predictive performance of volume-based PET parameters, recurrence-free survival was assessed using the Kaplan-Meier method. Results: The study included 70 males and 79 females with an average age of 65.8 years. The median follow-up time was 45.4 months. Recurrence was observed in 53 patients (35.6%). The mean ± SD SUVmax, MTV30%, and TLG30% of the entire cohort were 4.79 ± 2.94, 19.45 ± 24.85, and 56.43 ± 101.88, respectively. The cut-off values of MTV30% and TLG30% for recurrence were 11.07 ad 30.56, respectively. The 1-year recurrence-free survival (RFS) rate was 96.5% in low-MTV30% patients compared with 86.2% in high-MTV30% patients (p = 0.018) and 96.0% in low-TLG30% patients compared with 88.5% in high-TLG30% patients (p < 0.001). On univariate and multivariate analysis, TLG30% (HR, 2.828, p < 0.001; HR, 2.738, p < 0.001, respectively) was an independent prognostic factor for predicting recurrence-free survival (RFS). Conclusion: TLG30% value was observed to be a significant prognostic factor for RFS in patients with lung adenocarcinoma treated by surgical resection.

Original languageEnglish
Pages (from-to)453-461
Number of pages9
JournalNuclear Medicine and Molecular Imaging
Volume52
Issue number6
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Glucose
Recurrence
Fluorodeoxyglucose F18
Glycolysis
Tumor Burden
Survival
Positron Emission Tomography Computed Tomography
Adenocarcinoma of lung
Multivariate Analysis
Survival Rate
Neoplasms

Keywords

  • FDG PET/CT
  • Lung adenocarcinoma
  • Metabolic tumor volume
  • Recurrence
  • Total lesion glycolysis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{f034900460594823b267922c9f7f1667,
title = "Predictive Value of Preoperative Volume-Based 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Resectable Lung Adenocarcinoma",
abstract = "Purpose: This study aimed to investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which are volume-based PET parameters, using 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with surgically resectable lung adenocarcinoma. Methods: We retrospectively evaluated 149 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT before surgical resection. Maximum standardized uptake value (SUVmax), MTV, and TLG of the primary tumor with threshold value of SUVmax 30, 40, and 50{\%} were calculated, respectively. To compare the predictive performance of volume-based PET parameters, recurrence-free survival was assessed using the Kaplan-Meier method. Results: The study included 70 males and 79 females with an average age of 65.8 years. The median follow-up time was 45.4 months. Recurrence was observed in 53 patients (35.6{\%}). The mean ± SD SUVmax, MTV30{\%}, and TLG30{\%} of the entire cohort were 4.79 ± 2.94, 19.45 ± 24.85, and 56.43 ± 101.88, respectively. The cut-off values of MTV30{\%} and TLG30{\%} for recurrence were 11.07 ad 30.56, respectively. The 1-year recurrence-free survival (RFS) rate was 96.5{\%} in low-MTV30{\%} patients compared with 86.2{\%} in high-MTV30{\%} patients (p = 0.018) and 96.0{\%} in low-TLG30{\%} patients compared with 88.5{\%} in high-TLG30{\%} patients (p < 0.001). On univariate and multivariate analysis, TLG30{\%} (HR, 2.828, p < 0.001; HR, 2.738, p < 0.001, respectively) was an independent prognostic factor for predicting recurrence-free survival (RFS). Conclusion: TLG30{\%} value was observed to be a significant prognostic factor for RFS in patients with lung adenocarcinoma treated by surgical resection.",
keywords = "FDG PET/CT, Lung adenocarcinoma, Metabolic tumor volume, Recurrence, Total lesion glycolysis",
author = "Sunju Choi and Kwon, {Hye Ryeong} and Cho, {Hee Young} and Kisoo Pahk and Lee, {Sung Ho} and Chung, {Jae Ho} and Kwon, {Hyun Woo} and Sungeun Kim",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s13139-018-0555-4",
language = "English",
volume = "52",
pages = "453--461",
journal = "Nuclear Medicine and Molecular Imaging",
issn = "1869-3474",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Predictive Value of Preoperative Volume-Based 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Resectable Lung Adenocarcinoma

AU - Choi, Sunju

AU - Kwon, Hye Ryeong

AU - Cho, Hee Young

AU - Pahk, Kisoo

AU - Lee, Sung Ho

AU - Chung, Jae Ho

AU - Kwon, Hyun Woo

AU - Kim, Sungeun

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose: This study aimed to investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which are volume-based PET parameters, using 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with surgically resectable lung adenocarcinoma. Methods: We retrospectively evaluated 149 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT before surgical resection. Maximum standardized uptake value (SUVmax), MTV, and TLG of the primary tumor with threshold value of SUVmax 30, 40, and 50% were calculated, respectively. To compare the predictive performance of volume-based PET parameters, recurrence-free survival was assessed using the Kaplan-Meier method. Results: The study included 70 males and 79 females with an average age of 65.8 years. The median follow-up time was 45.4 months. Recurrence was observed in 53 patients (35.6%). The mean ± SD SUVmax, MTV30%, and TLG30% of the entire cohort were 4.79 ± 2.94, 19.45 ± 24.85, and 56.43 ± 101.88, respectively. The cut-off values of MTV30% and TLG30% for recurrence were 11.07 ad 30.56, respectively. The 1-year recurrence-free survival (RFS) rate was 96.5% in low-MTV30% patients compared with 86.2% in high-MTV30% patients (p = 0.018) and 96.0% in low-TLG30% patients compared with 88.5% in high-TLG30% patients (p < 0.001). On univariate and multivariate analysis, TLG30% (HR, 2.828, p < 0.001; HR, 2.738, p < 0.001, respectively) was an independent prognostic factor for predicting recurrence-free survival (RFS). Conclusion: TLG30% value was observed to be a significant prognostic factor for RFS in patients with lung adenocarcinoma treated by surgical resection.

AB - Purpose: This study aimed to investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which are volume-based PET parameters, using 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with surgically resectable lung adenocarcinoma. Methods: We retrospectively evaluated 149 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT before surgical resection. Maximum standardized uptake value (SUVmax), MTV, and TLG of the primary tumor with threshold value of SUVmax 30, 40, and 50% were calculated, respectively. To compare the predictive performance of volume-based PET parameters, recurrence-free survival was assessed using the Kaplan-Meier method. Results: The study included 70 males and 79 females with an average age of 65.8 years. The median follow-up time was 45.4 months. Recurrence was observed in 53 patients (35.6%). The mean ± SD SUVmax, MTV30%, and TLG30% of the entire cohort were 4.79 ± 2.94, 19.45 ± 24.85, and 56.43 ± 101.88, respectively. The cut-off values of MTV30% and TLG30% for recurrence were 11.07 ad 30.56, respectively. The 1-year recurrence-free survival (RFS) rate was 96.5% in low-MTV30% patients compared with 86.2% in high-MTV30% patients (p = 0.018) and 96.0% in low-TLG30% patients compared with 88.5% in high-TLG30% patients (p < 0.001). On univariate and multivariate analysis, TLG30% (HR, 2.828, p < 0.001; HR, 2.738, p < 0.001, respectively) was an independent prognostic factor for predicting recurrence-free survival (RFS). Conclusion: TLG30% value was observed to be a significant prognostic factor for RFS in patients with lung adenocarcinoma treated by surgical resection.

KW - FDG PET/CT

KW - Lung adenocarcinoma

KW - Metabolic tumor volume

KW - Recurrence

KW - Total lesion glycolysis

UR - http://www.scopus.com/inward/record.url?scp=85057550778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057550778&partnerID=8YFLogxK

U2 - 10.1007/s13139-018-0555-4

DO - 10.1007/s13139-018-0555-4

M3 - Article

VL - 52

SP - 453

EP - 461

JO - Nuclear Medicine and Molecular Imaging

JF - Nuclear Medicine and Molecular Imaging

SN - 1869-3474

IS - 6

ER -